Israel’s BiomX raises $24 mln in private funding round: Reuters

BiomX, which is developing drugs using microbiome bacteria, said on Monday it raised $24 million in an early stage funding round led by OrbiMed, Jonhnson & Johnson Innovation and Takeda Ventures.

Seventure Partners, MiraeAsset, SBI Japan-Israel Innovation Fund and other European investors also participated, the Israel-based company said.

The funds will be used to advance the firm’s therapeutic pipeline towards clinical stages.

BiomX develops treatments to alleviate diseases stemming from an imbalance in the microbiome – the bacteria in the human body. Its pipeline consists of products for the treatment of acne, inflammatory bowel disease and cancer.